Kidney Protection with Dapagliflozin in Type 2 Diabetes

Primary Renal Protection Evidence

• The DAPA-CKD trial demonstrated a 39% reduction in the composite outcome of sustained decline in eGFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes over 2.4 years, with a hazard ratio of 0.61 (95% CI 0.51-0.72) in patients with CKD (UACR 200-5,000 mg/g and eGFR 25-75 mL/min/1.73 m²), both with and without diabetes 1
• Dapagliflozin reduced the risk of the renal-specific composite outcome (sustained decline in eGFR ≥50%, end-stage kidney disease, or renal death) by 44% (HR 0.56; 95% CI 0.45-0.68) 1

Guideline-Based Recommendations for Use

• The American Diabetes Association and European Association for the Study of Diabetes recommend using SGLT2 inhibitors like dapagliflozin for kidney protection in patients with type 2 diabetes and CKD with UACR >300 mg/g and eGFR 30-90 mL/min/1.73 m², with the strongest evidence for benefit 2
• Patients with eGFR 30 to ≤60 mL/min/1.73 m² or UACR >30 mg/g should be considered for SGLT2 inhibitor therapy, according to the American Diabetes Association and European Association for the Study of Diabetes 2
• The decision to use dapagliflozin for kidney protection should be made independently of baseline HbA1c or glycemic targets, as recommended by the American Diabetes Association and European Association for the Study of Diabetes 2, 3

Additional Cardiovascular and Renal Benefits

• Dapagliflozin demonstrated a 17% reduction in cardiovascular death or hospitalization for heart failure (HR 0.83; 95% CI 0.73-0.95) 4

Practical Implementation

• The American College of Cardiology recommends starting dapagliflozin 10 mg once daily in patients with type 2 diabetes with eGFR ≥25 mL/min/1.73 m² and evidence of kidney disease (albuminuria or reduced eGFR) 1
• Dapagliflozin should not be used in patients with eGFR <25 mL/min/1.73 m², as it is unlikely to be effective 1

Safety Considerations for Kidney Protection Use

• The European Association for the Study of Diabetes recommends monitoring for volume depletion, particularly in patients with baseline eGFR 30-60 mL/min/1.73 m² 3

Comparison to Other SGLT2 Inhibitors

• The kidney protective effects of dapagliflozin are independent of its glucose-lowering effects, as demonstrated by consistent benefits in patients with and without diabetes and across all HbA1c levels, according to the American Diabetes Association and European Association for the Study of Diabetes 2, 3

Cardiovascular and Renal Benefits of Dapagliflozina in Patients with Type 2 Diabetes

Introduction to Dapagliflozina Benefits

• The American College of Cardiology recommends dapagliflozina for reducing the risk of hospitalization for heart failure, major adverse cardiovascular events (MACE), and progression of kidney disease in patients with type 2 diabetes, regardless of baseline HbA1c levels 5, 6

Cardiovascular Outcomes

• The DECLARE-TIMI 58 study evaluated dapagliflozina 10 mg daily versus placebo in 17,160 patients with type 2 diabetes, with a median follow-up of 4.2 years, and demonstrated cardiovascular safety but not superiority for the primary endpoint of MACE (HR 0.93; 95% CI 0.84-1.03) 5, 6
• Dapagliflozina showed a significant benefit for the co-primary endpoint of cardiovascular death or hospitalization for heart failure (HR 0.83; 95% CI 0.73-0.95) 5, 6
• Hospitalization for heart failure was significantly reduced (HR 0.73; 95% CI 0.61-0.88) 5, 7

Renal Outcomes

• Dapagliflozina showed a significant 47% reduction in the risk of composite renal events (HR 0.53; 95% CI 0.43-0.66) 5, 6
• In patients with chronic kidney disease (CKD), dapagliflozina significantly reduced the risk of a composite outcome of sustained decline in eGFR of at least 50%, end-stage renal disease, or death from renal or cardiovascular causes (HR 0.61; 95% CI 0.51-0.72) 8, 9

Mortality

• Dapagliflozina did not show a statistically significant reduction in all-cause mortality in the DECLARE-TIMI 58 study (HR 0.93; 95% CI 0.82-1.04) 5, 6
• However, in the DAPA-HF study, a significant reduction in all-cause mortality was observed (HR 0.83; 95% CI 0.71-0.97) 5, 6

Clinical Practice Considerations

• The American College of Cardiology indicates dapagliflozina for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise 6
• Dapagliflozina is also indicated for reducing the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors 6

Renal Benefits of Dapagliflozin

Primary Renal Protection Evidence

• The American College of Cardiology recommends that patients with chronic kidney disease (CKD) and eGFR 25-75 mL/min/1.73 m², with or without diabetes, should receive dapagliflozin to reduce the risk of kidney disease progression, with a 39-44% reduction in the composite outcome of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death over 2.4 years 10
• Dapagliflozin reduced the composite outcome of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61; 95% CI 0.51-0.72) in patients with CKD, with a moderate to high strength of evidence 10
• The renal-specific composite outcome (sustained eGFR decline ≥50%, ESKD, or renal death) was reduced by 44% (HR 0.56; 95% CI 0.45-0.68) in patients with CKD, with a moderate to high strength of evidence 10

Guideline-Based Recommendations for Renal Protection

• The American Diabetes Association recommends SGLT2 inhibitors like dapagliflozin for kidney protection in patients with type 2 diabetes and CKD, with the strongest evidence for those with UACR >300 mg/g and eGFR 30-90 mL/min/1.73 m², with a high strength of evidence 11
• The decision to use dapagliflozin for kidney protection should be made independently of baseline HbA1c or glycemic targets, as the renal benefits are independent of glucose-lowering effects, with a moderate strength of evidence 11, 12

Additional Cardiovascular Benefits in CKD Patients

• Dapagliflozin reduced cardiovascular death or hospitalization for heart failure by 29% (HR 0.71; 95% CI 0.55-0.92) in the DAPA-CKD trial, with a moderate strength of evidence 10
• Dapagliflozin reduced all-cause mortality by 31% (HR 0.69; 95% CI 0.53-0.88) in the DAPA-CKD trial, with a moderate strength of evidence 10

Mechanism of Renal Protection

• The renal protective effects of dapagliflozin are independent of glucose-lowering, with benefits consistent in patients with and without diabetes and across all HbA1c levels, with a moderate strength of evidence 12